| [1] |
Leung SY，Yuen ST，Chu KM,et al.Expression profiling identifies chemokine (C-C motif) ligand 18 asan independent prognostic indicator in gastric cancer[J].Gastroenterology，2004,127(2):457-69.
|
| [2] |
Schutyser E,Struyf S,Proost P,et al.Identification of biologically active chemokine isoformsfrom ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine inovarian carcinoma[J].J Biol Chem,2002,277(27):24584-93.
|
| [3] |
Mantovani A.The chemokine system:redundancy for robust outputs [J].Immunol Today,1999,20(6):254-7.
|
| [4] |
Busse D，Doughty RS,Arteaga CL.HER-2/neu (erbB-2) and the cell cycle [J].Semin Oncol，2000，27(6 Suppl 11):3-8.
|
| [5] |
Miglietta A，Cayalli R，Bocca C,et al.Cellular uptake and cytotoxicity of solid lipidnanospheres (SLN) incorporating doxorubicin or paclitaxel [J].Int J Pharm，2000,210(1-2):61-7.
|
| [6] |
Adema GJ,Hartgers F,Verstraten R,et al.A dendritic-cell-derived C-C chemokine thatpreferentially attracts naive T cells [J].Nature,1997,387 (6634):713-7.
|
| [7] |
Guan P,Burghes AH,Cunningham A,et al.Genomic organization and biological characterization ofthe novel human CC chemokine DC-CK-1/PARC/MIP-4/SCYA18 [J].Genomics,1999,56(3):296-302.
|
| [8] |
Tasaki Y,Fukuda S,Lio M,et al.Chemokine PARC gene (SCYA18) generated by fusion of two MIP-1alpha/LD78alpha-like genes[J].Genomics,1999,55(3):353-7.
|
| [9] |
Shilling V，Jenkins V，Morris R，et al.The effects of adjuvant chemotherapy on cognition inwomen with breast cancer--preliminary results of an observational longitudinal study [J].Breast，2005,14(2):142-50.
|
| [10] |
Budman DR.Dose and schedule as determinants of outcomes in chemotherapy for breast cancer[J].Semin Oncol，2004,31(6 Suppl 15):3-9.
|
| [11] |
Charfare H，Limongelli S，Purushotham AD，et al.Neoadjuvant chemotherapy in breast cancer [J].Br J Surg，2005,92(1):14-23.
|
| [12] |
Opdenakker G,Van den Steen PE,Laureys G,et al.Neutralizing antibodies in gene-defective hosts[J].Trends Immunol,2003,24(2):94-100.
|
| [13] |
Struyf S,Schutyser E,Gouwy M,et al.CCL18 8／CCL18 is a plasma CC chemokine with increasedlevels in childhood acute lymphoblastic leukemia [J].Am J Pathol,2003,163(5):2065-75.
|
| [14] |
Colcher D，Bird R，Roselli M，et al.In vivo tumor targeting of a recombinant single-chainantigen-binding protein[J].J Natl Cancer Inst，1990,82(14):1191-7.
|
| [15] |
Wu AM，Senter PD.Arming antibodies:Prospects and challenges for immunoconjugates [J].NatBiotechnol，2005，23 (9):1137-46.
|
| [16] |
Lin Y，Huang R，Chen L，et al.Identification of interleukin-8 as estrogen receptor-regulatedfactor involved in breast cancer invasion and angiogenesis by protein arrays [J].Int JCancer,2004,109(4):507-15.
|
| [17] |
Lazennec G，Bresson D，Lucas A，et al.ER beta inhibits proliferation and invasion of breastcancer cells [J].Endocrinology，2001,142(9):4120-30.
|
| [18] |
Cheng J，Lee EJ，Madison LD，et al.Expression of estrogen receptor beta in prostate carcinomacells inhibits invasion and proliferation and triggers apoptosis [J].FEBF Lett，2004,566(1-3):169-72.
|
| [19] |
Lazennec G.Estrogen receptor beta，a possible tumor suppressor involved in ovariancarcinogenesis [J].Cancer Lett，2006,231(2):151-7.
|
| [20] |
Ravdin PM，Chamness GC.The c-erbB-2 proto-oncogene as a prognostic and predictive marker inbreast cancer:a paradigm for the development of other macromolecular markers-a review [J].Gene，1995,159(1):19-27.
|
| [21] |
Petit T，Wilt M,Velten M,et al.Comparative value of tumour grade，hormonal receptors，Ki-67，HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated withneoadjuvant anthracycline-based chemotherapy [J].Eur J Cancer，2004,40(2):205-11.
|
下载:
